UDkt Naoya Yamazaki I-dermatologic Oncology
Umxhumanisi - I-Dermatologic Oncology, Isipiliyoni:
Ukuqokwa kwencwadiMayelana noDokotela
UDkt. Naoya Yamazaki uphakathi kochwepheshe bomdlavuza wesikhumba ohamba phambili e-Tokyo, eJapane.
UDkt. Naoya Yamazaki uhlotshaniswa ne-National Cancer Center Hospital, e-Japan.
Isibhedlela
Isikhungo Somdlavuza Kazwelonke, eJapane
Ubuchwepheshe
- I-dermatologic Oncology
Izinqubo ezenziwayo
- I-dermatologic Oncology
- I-Melanoma
Ucwaningo Nokushicilelwa
- I-Adjuvant Nivolumab Versus Ipilimumab ku-Resected Stage III noma IV Melanoma
- I-Encorafenib Plus Binimetinib Versus Vemurafenib noma i-Encorafenib Ezigulini ezine-BRAF-mutant Melanoma (COLUMBUS): I-Multicentre, Open-Label, Isigaba sesi-3 Esingahleliwe
-
Ukusinda Sekukonke Ezigulini Ezine-BRAF-mutant Melanoma Ethola I-Encorafenib Plus Binimetinib Versus Vemurafenib noma i-Encorafenib (COLUMBUS): I-Multicentre, Open-Label, Randomised, Isigaba sesi-3 Sokulinga
-
Ukwelashwa Okuqondisiwe kanye Ne-Immunotherapy ye-Melanoma e-Japan
-
I-YAP1-MAML2 evamile kanye ne-YAP1-NUTM1 Fusion ku-Poroma ne-Porocarcinoma